Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
Nature relatedness
psilocybin
psychedelics
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pubmed:
6
1
2023
medline:
11
1
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
Past research reports a positive relationship between experience with classic serotonergic psychedelics and nature relatedness (NR). However, these studies typically do not distinguish between different psychedelic compounds, which have a unique psychopharmacology and may be used in specific contexts and with different intentions. Likewise, it is not clear whether these findings can be attributed to substance use per se or unrelated variables that differentiate psychedelic users from nonusers. The present study was designed to determine the relative degree to which lifetime experience with different psychedelic substances is predictive of self-reported NR among psychedelic-experienced users. We conducted a combined reanalysis of five independent datasets ( Among people experienced with psychedelics, only past use of psilocybin (versus LSD, mescaline, Results suggest that experience with psilocybin is the only reliable (and strongest) predictor of NR. Future research should focus on psilocybin when investigating effects of psychedelic on NR and determine whether pharmacological attributes or differences in user expectations/use settings are responsible for this observation.
Sections du résumé
BACKGROUND
Past research reports a positive relationship between experience with classic serotonergic psychedelics and nature relatedness (NR). However, these studies typically do not distinguish between different psychedelic compounds, which have a unique psychopharmacology and may be used in specific contexts and with different intentions. Likewise, it is not clear whether these findings can be attributed to substance use per se or unrelated variables that differentiate psychedelic users from nonusers.
AIMS
The present study was designed to determine the relative degree to which lifetime experience with different psychedelic substances is predictive of self-reported NR among psychedelic-experienced users.
METHODS
We conducted a combined reanalysis of five independent datasets (
RESULTS/OUTCOMES
Among people experienced with psychedelics, only past use of psilocybin (versus LSD, mescaline,
CONCLUSIONS/INTERPRETATION
Results suggest that experience with psilocybin is the only reliable (and strongest) predictor of NR. Future research should focus on psilocybin when investigating effects of psychedelic on NR and determine whether pharmacological attributes or differences in user expectations/use settings are responsible for this observation.
Identifiants
pubmed: 36601974
doi: 10.1177/02698811221146356
pmc: PMC9834326
doi:
Substances chimiques
Hallucinogens
0
Psilocybin
2RV7212BP0
Lysergic Acid Diethylamide
8NA5SWF92O
N,N-Dimethyltryptamine
WUB601BHAA
Mescaline
RHO99102VC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-106Références
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84
pubmed: 24309097
Front Psychol. 2014 Sep 08;5:976
pubmed: 25249992
Curr Top Behav Neurosci. 2018;36:393-430
pubmed: 28401522
Neuropsychopharmacology. 2016 Oct;41(11):2638-46
pubmed: 27249781
J Psychoactive Drugs. 2020 Sep-Oct;52(4):309-318
pubmed: 32511073
Psychopharmacology (Berl). 2005 Jul;180(3):427-35
pubmed: 15723230
J Psychopharmacol. 2018 Jan;32(1):49-69
pubmed: 29020861
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
J Psychopharmacol. 2008 Aug;22(6):603-20
pubmed: 18593734
Int J Environ Res Public Health. 2019 Dec 16;16(24):
pubmed: 31888300
Sci Rep. 2020 Feb 10;10(1):2214
pubmed: 32042038
Front Psychol. 2013 Nov 01;4:813
pubmed: 24198806
Psychopharmacology (Berl). 2011 Dec;218(4):649-65
pubmed: 21674151
Cell. 2017 Jan 26;168(3):377-389.e12
pubmed: 28129538
Sci Rep. 2021 Jan 21;11(1):1941
pubmed: 33479342
Front Neurosci. 2018 Jan 22;12:7
pubmed: 29403350
J Psychopharmacol. 2018 Jul;32(7):756-769
pubmed: 29938565
Neuropharmacology. 2011 Sep;61(3):364-81
pubmed: 21256140
Conserv Biol. 2020 Feb;34(1):180-193
pubmed: 31251416
J Nerv Ment Dis. 1963 Dec;137:561-73
pubmed: 14087676
J Health Psychol. 2016 Jul;21(7):1436-45
pubmed: 25370570
Am J Addict. 1999 Summer;8(3):234-42
pubmed: 10506904
J Psychopharmacol. 2017 Aug;31(8):975-988
pubmed: 28631526
Front Integr Neurosci. 2018 Nov 08;12:54
pubmed: 30467466
Front Psychol. 2022 Mar 28;13:852248
pubmed: 35418909
Neuropharmacology. 2015 Dec;99:675-88
pubmed: 26302653
AMA Arch Gen Psychiatry. 1959 Jul;1:58-69
pubmed: 13842570
Psychopharmacology (Berl). 2020 May;237(5):1371-1382
pubmed: 32144438
J Health Psychol. 2012 Apr;17(3):379-88
pubmed: 21859800
Drug Alcohol Rev. 2019 Nov;38(7):781-789
pubmed: 31489731
J Psychopharmacol. 2011 Nov;25(11):1434-52
pubmed: 20855349
Public Underst Sci. 2021 Apr;30(3):302-318
pubmed: 33356921
Neurosci Biobehav Rev. 2020 Jun;113:179-189
pubmed: 32194129
Nature. 2008 May 15;453(7193):353-7
pubmed: 18480817
J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191
pubmed: 28443703
J Psychiatr Res. 2021 May;137:273-282
pubmed: 33730602
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
J Affect Disord. 2019 Nov 1;258:11-24
pubmed: 31382100
J Psychoactive Drugs. 2022 Aug 19;:1-9
pubmed: 35984245
J Psychopharmacol. 2018 Jul;32(7):725-731
pubmed: 29446697
PLoS One. 2012;7(2):e30800
pubmed: 22363492
J Psychopharmacol. 2016 Dec;30(12):1259-1267
pubmed: 27852960
Compr Psychiatry. 1962 Aug;3:235-42
pubmed: 13908449
J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
pubmed: 16803859
Psychopharmacologia. 1961;2:147-59
pubmed: 13717955
Int J Psychol. 2014 Jun;49(3):141-57
pubmed: 24821503
Curr Biol. 2016 Apr 25;26(8):1043-50
pubmed: 27085214
AMA Arch Gen Psychiatry. 1959 Sep;1:279-82
pubmed: 13796178
Neurosci Biobehav Rev. 2018 Apr;87:118-132
pubmed: 29452127
Biochem Pharmacol. 2008 Jan 1;75(1):17-33
pubmed: 17977517
Front Pharmacol. 2018 Nov 02;9:897
pubmed: 30450045
Health Psychol Open. 2020 Dec 6;7(2):2055102920978123
pubmed: 33335742
PLoS One. 2010 Feb 02;5(2):e9019
pubmed: 20126400
Hum Brain Mapp. 2016 Sep;37(9):3203-13
pubmed: 27151536
Neuropsychopharmacology. 2022 May;47(6):1180-1187
pubmed: 35217796
J Psychopharmacol. 2011 Nov;25(11):1453-61
pubmed: 21956378
Sci Adv. 2022 Mar 18;8(11):eabl6989
pubmed: 35294242
J Psychoactive Drugs. 2005 Jun;37(2):209-18
pubmed: 16149335
Lancet. 2021 Oct 30;398(10311):1619-1662
pubmed: 34687662
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2338-2346
pubmed: 31964815
J Psychopharmacol. 2018 Jul;32(7):811-819
pubmed: 29338538
PLoS One. 2010 Aug 31;5(8):e12412
pubmed: 20824211